Fig. 1
From: Replacing what’s lost: a new era of stem cell therapy for Parkinson’s disease
Schematic of workflow for derivation of therapeutic-grade dopaminergic precursors. Undifferentiated iPSCs are propagated and differentiated on cGMP-grade laminin-511 fragments that are xeno-free. Sorting for CORIN-expressing cells ensures a highly-enriched population of floorplate progenitors are used for subsequent expansion and differentiation. Large numbers of purified dopaminergic precursors would be obtained, providing enough material for transplantation of 4.8 million cells per patient. Each patient from the CiRA clinical trial would be observed for at least 2 years after transplantation